Star Scientific, Inc. (CIGX: Quote) said Monday that its subsidiary, Rock Creek Pharmaceuticals, Inc., completed the first successful human clinical trial showing that Antabloc, a dietary supplement to provide anti-inflammatory support, lowers C-reactive proteins or CRP levels in subjects' blood.
The company reported initial results from Phase 2 of the RCP-006 study.
The trial was conducted among 105 subjects. All the subjects were smokers and 79 percent were overweight or obese.
CRP is a molecule produced by the liver in response to an inflammatory signal, and is a marker for inflammation.
Phase 2 data analysis examined the CRP and anatabine levels in the subjects' blood, first to establish a baseline, and then to assess levels with Anatabloc dosing. Results showed that CRP levels in subjects with dose-appropriate anatabine levels were about 30% lower than CRP levels among those with low anatabine levels.
Phase 2 of the study was an open-label extension in which subjects were instructed to take two Anatabloc tablets three times per day for two weeks. In Phase 2, subjects continued to smoke, but took the 6 tablets per day of Anatabloc. Phase 3, a longer open-label extension, is ongoing.
Phase 1 of the study was a one-day trial to assess whether Anatabloc was as successful as CigRx, the company's other dietary supplement, in reducing the urge to smoke, and results showed that CigRx and Anatabloc were equally effective.
Star Scientific is a technology-oriented company with a mission to reduce the harm associated with tobacco at every level.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org